CYBN Cybin Inc

19
Price
$7.57
Decreased by -2.20%
Dollar volume (20D)
4.04 M
ADR%
6.97
Shares float
19.01 M
Shares short
2.18 M [11.45%]
Shares outstanding
23.02 M
Market cap
184.72 M
Beta
1.13
Price/earnings
N/A
20D range
7.28 9.83
50D range
6.50 9.83
200D range
4.81 13.88

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.

The company has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.

The company is headquartered in Toronto, Canada.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Jul 1, 25 -1.46
Decreased by -7.20 K%
-0.02
Decreased by -5.79 K%
Mar 31, 25 -1.46
Decreased by -4.35 K%
-1.23
Decreased by -18.70%
Feb 11, 25 -0.53
Decreased by -488.89%
-0.03
Decreased by -1.92 K%
Nov 13, 24 -2.86
Decreased by -5.62 K%
-0.02
Decreased by -11.43 K%
Aug 8, 24 -0.02
Increased by +71.43%
-0.02
Jun 25, 24 -0.03
Increased by +53.14%
-0.03
Decreased by -9.33%
Feb 14, 24 -0.09
Decreased by -50.00%
-0.04
Decreased by -125.00%
Nov 13, 23 -0.05
Increased by +16.67%
-0.05
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 N/A
Decreased by N/A%
-30.58 M
Decreased by -106.28%
- -
Mar 31, 25 0.00
Decreased by N/A%
-30.58 M
Decreased by -43.25%
Decreased by N/A%
Decreased by N/A%
Dec 31, 24 0.00
Decreased by N/A%
-10.54 M
Increased by +65.24%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by N/A%
-57.19 M
Decreased by -381.01%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by N/A%
-14.82 M
Decreased by -19.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by N/A%
-21.35 M
Decreased by -55.58%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 0.00
Decreased by N/A%
-30.33 M
Decreased by -182.35%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-11.89 M
Decreased by -19.22%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY